Marco Gobbi

机构：Mario Negri Institute for Pharmacological Research · ORCID：0000-0003-0756-109X

发表论文 339 篇 · 总被引 7906 次 · h-index 46

代表论文

• Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients (2023 · Leukemia · 被引 63)
• Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy (2022 · Blood · 被引 39)
• Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study (2023 · Blood Advances · 被引 28)
• Nature of the Interaction of Alpha-D-Mannose and Escherichia coli Bacteria, and Implications for its Regulatory Classification. A Delphi Panel European Consensus Based on Chemistry and Legal Evidence (2023 · Therapeutic Innovation & Regulatory Science · 被引 4)
• Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients (2023 · Leukemia · 被引 2)
• P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (2023 · HemaSphere · 被引 1)